Pharmaceutical company Mayne Pharma Group
(ASX:MYX) released their half year results today showing underlying net profit after tax up 35 per cent to $21.1 million from the prior corresponding period.
Revenue increased 13 per cent from the last half year to $274.4 million.
And underlying EBITDA rose 16 per cent to $81.2 million.
During the half, the Company received FDA approval for two products including the New Drug Application for TOLSURA an anti-fungal capsule which launched in the US in January this year.
The Directors have not declared an interim dividend in relation to the period ended 31 December 2018.
Shares in Mayne Pharma Group
(ASX:MYX) are trading 5 per cent lower to 76 cents.
